(LYB) LyondellBasell Industries - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: NL0009434992
Stock: Plastics, Chemicals, Fuels, Technology
Total Rating 26
Risk 71
Buy Signal -0.27
| Risk 5d forecast | |
|---|---|
| Volatility | 41.6% |
| Relative Tail Risk | -5.56% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.14 |
| Alpha | -30.37 |
| Character TTM | |
|---|---|
| Beta | 0.894 |
| Beta Downside | 2.036 |
| Drawdowns 3y | |
|---|---|
| Max DD | 55.35% |
| CAGR/Max DD | -0.16 |
EPS (Earnings per Share)
Revenue
Description: LYB LyondellBasell Industries March 04, 2026
LyondellBasell Industries N.V. (LYB) is a global chemical company with operations across multiple continents. It is structured into five segments, covering various chemical products and technologies.
The companys product portfolio includes olefins, polyolefins (polyethylene, polypropylene), and intermediate chemicals like propylene oxide and styrene monomer. These are foundational materials in the chemical industry, often used as building blocks for other products. The business model involves both manufacturing and licensing chemical process technologies, a common practice in the specialty chemicals sector.
LYB also produces advanced polymer solutions, such as polypropylene compounds and engineered plastics. These materials serve diverse end markets, including food packaging, automotive, and paints. The chemical industry is cyclical, with demand often tied to global economic growth and industrial production. Further research on ValueRay can provide more in-depth financial analysis.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: -743.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 1.11 > 1.0 |
| NWC/Revenue: 15.72% < 20% (prev 15.85%; Δ -0.13% < -1%) |
| CFO/TA 0.07 > 3% & CFO 2.26b > Net Income -743.0m |
| Net Debt (12.51b) to EBITDA (1.19b): 10.56 < 3 |
| Current Ratio: 1.77 > 1.5 & < 3 |
| Outstanding Shares: last quarter (322.0m) vs 12m ago -1.23% < -2% |
| Gross Margin: 9.00% > 18% (prev 0.13%; Δ 887.3% > 0.5%) |
| Asset Turnover: 86.46% > 50% (prev 98.15%; Δ -11.68% > 0%) |
| Interest Coverage Ratio: -0.40 > 6 (EBITDA TTM 1.19b / Interest Expense TTM 507.0m) |
Altman Z'' 1.77
| A: 0.14 (Total Current Assets 10.87b - Total Current Liabilities 6.13b) / Total Assets 34.00b |
| B: 0.20 (Retained Earnings 6.81b / Total Assets 34.00b) |
| C: -0.01 (EBIT TTM -205.0m / Avg Total Assets 34.87b) |
| D: 0.23 (Book Value of Equity 5.52b / Total Liabilities 23.80b) |
| Altman-Z'' Score: 1.77 = BBB |
Beneish M -2.95
| DSRI: 0.92 (Receivables 2.81b/3.55b, Revenue 30.15b/35.08b) |
| GMI: 1.45 (GM 9.00% / 13.08%) |
| AQI: 0.88 (AQ_t 0.17 / AQ_t-1 0.19) |
| SGI: 0.86 (Revenue 30.15b / 35.08b) |
| TATA: -0.09 (NI -743.0m - CFO 2.26b) / TA 34.00b) |
| Beneish M-Score: -2.95 (Cap -4..+1) = A |
What is the price of LYB shares?
As of March 04, 2026, the stock is trading at USD 58.21 with a total of 6,807,076 shares traded.
Over the past week, the price has changed by +1.02%, over one month by +10.23%, over three months by +28.00% and over the past year by -11.84%.
Over the past week, the price has changed by +1.02%, over one month by +10.23%, over three months by +28.00% and over the past year by -11.84%.
Is LYB a buy, sell or hold?
LyondellBasell Industries has received a consensus analysts rating of 3.27.
Therefor, it is recommend to hold LYB.
- StrongBuy: 5
- Buy: 1
- Hold: 13
- Sell: 1
- StrongSell: 2
What are the forecasts/targets for the LYB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 51.2 | -12.1% |
| Analysts Target Price | 51.2 | -12.1% |
LYB Fundamental Data Overview February 28, 2026
P/E Forward = 12.987
P/S = 0.6015
P/B = 1.3323
P/EG = 0.8541
Revenue TTM = 30.15b USD
EBIT TTM = -205.0m USD
EBITDA TTM = 1.19b USD
Long Term Debt = 12.12b USD (from longTermDebt, last quarter)
Short Term Debt = 1.18b USD (from shortTermDebt, last quarter)
Debt = 15.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.51b USD (from netDebt column, last quarter)
Enterprise Value = 30.65b USD (18.14b + Debt 15.96b - CCE 3.45b)
Interest Coverage Ratio = -0.40 (Ebit TTM -205.0m / Interest Expense TTM 507.0m)
EV/FCF = 13.55x (Enterprise Value 30.65b / FCF TTM 2.26b)
FCF Yield = 7.38% (FCF TTM 2.26b / Enterprise Value 30.65b)
FCF Margin = 7.50% (FCF TTM 2.26b / Revenue TTM 30.15b)
Net Margin = -2.46% (Net Income TTM -743.0m / Revenue TTM 30.15b)
Gross Margin = 9.00% ((Revenue TTM 30.15b - Cost of Revenue TTM 27.44b) / Revenue TTM)
Gross Margin QoQ = 6.49% (prev 11.73%)
Tobins Q-Ratio = 0.90 (Enterprise Value 30.65b / Total Assets 34.00b)
Interest Expense / Debt = 0.67% (Interest Expense 107.0m / Debt 15.96b)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.9m (EBIT -205.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.77 (Total Current Assets 10.87b / Total Current Liabilities 6.13b)
Debt / Equity = 1.58 (Debt 15.96b / totalStockholderEquity, last quarter 10.08b)
Debt / EBITDA = 10.56 (Net Debt 12.51b / EBITDA 1.19b)
Debt / FCF = 5.53 (Net Debt 12.51b / FCF TTM 2.26b)
Total Stockholder Equity = 11.20b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.13% (Net Income -743.0m / Total Assets 34.00b)
RoE = -6.63% (Net Income TTM -743.0m / Total Stockholder Equity 11.20b)
RoCE = -0.88% (EBIT -205.0m / Capital Employed (Equity 11.20b + L.T.Debt 12.12b))
RoIC = -0.70% (negative operating profit) (NOPAT -161.9m / Invested Capital 23.16b)
WACC = 5.15% (E(18.14b)/V(34.10b) * Re(9.21%) + D(15.96b)/V(34.10b) * Rd(0.67%) * (1-Tc(0.21)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.62%
[DCF] Terminal Value 80.82% ; FCFF base≈2.15b ; Y1≈1.41b ; Y5≈643.7m
[DCF] Fair Price = 24.82 (EV 20.51b - Net Debt 12.51b = Equity 8.00b / Shares 322.2m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -83.03 | EPS CAGR: -58.05% | SUE: -3.95 | # QB: 0
Revenue Correlation: -92.94 | Revenue CAGR: -15.20% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.80 | Chg7d=+0.000 | Chg30d=-0.163 | Revisions Net=-6 | Analysts=15
EPS current Year (2026-12-31): EPS=2.62 | Chg7d=+0.062 | Chg30d=-0.708 | Revisions Net=-6 | Growth EPS=+54.4% | Growth Revenue=-2.6%
EPS next Year (2027-12-31): EPS=3.77 | Chg7d=-0.052 | Chg30d=-0.810 | Revisions Net=-8 | Growth EPS=+43.6% | Growth Revenue=+0.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Next Quarter)
P/S = 0.6015
P/B = 1.3323
P/EG = 0.8541
Revenue TTM = 30.15b USD
EBIT TTM = -205.0m USD
EBITDA TTM = 1.19b USD
Long Term Debt = 12.12b USD (from longTermDebt, last quarter)
Short Term Debt = 1.18b USD (from shortTermDebt, last quarter)
Debt = 15.96b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.51b USD (from netDebt column, last quarter)
Enterprise Value = 30.65b USD (18.14b + Debt 15.96b - CCE 3.45b)
Interest Coverage Ratio = -0.40 (Ebit TTM -205.0m / Interest Expense TTM 507.0m)
EV/FCF = 13.55x (Enterprise Value 30.65b / FCF TTM 2.26b)
FCF Yield = 7.38% (FCF TTM 2.26b / Enterprise Value 30.65b)
FCF Margin = 7.50% (FCF TTM 2.26b / Revenue TTM 30.15b)
Net Margin = -2.46% (Net Income TTM -743.0m / Revenue TTM 30.15b)
Gross Margin = 9.00% ((Revenue TTM 30.15b - Cost of Revenue TTM 27.44b) / Revenue TTM)
Gross Margin QoQ = 6.49% (prev 11.73%)
Tobins Q-Ratio = 0.90 (Enterprise Value 30.65b / Total Assets 34.00b)
Interest Expense / Debt = 0.67% (Interest Expense 107.0m / Debt 15.96b)
Taxrate = 21.0% (US default 21%)
NOPAT = -161.9m (EBIT -205.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.77 (Total Current Assets 10.87b / Total Current Liabilities 6.13b)
Debt / Equity = 1.58 (Debt 15.96b / totalStockholderEquity, last quarter 10.08b)
Debt / EBITDA = 10.56 (Net Debt 12.51b / EBITDA 1.19b)
Debt / FCF = 5.53 (Net Debt 12.51b / FCF TTM 2.26b)
Total Stockholder Equity = 11.20b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.13% (Net Income -743.0m / Total Assets 34.00b)
RoE = -6.63% (Net Income TTM -743.0m / Total Stockholder Equity 11.20b)
RoCE = -0.88% (EBIT -205.0m / Capital Employed (Equity 11.20b + L.T.Debt 12.12b))
RoIC = -0.70% (negative operating profit) (NOPAT -161.9m / Invested Capital 23.16b)
WACC = 5.15% (E(18.14b)/V(34.10b) * Re(9.21%) + D(15.96b)/V(34.10b) * Rd(0.67%) * (1-Tc(0.21)))
Discount Rate = 9.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -0.62%
[DCF] Terminal Value 80.82% ; FCFF base≈2.15b ; Y1≈1.41b ; Y5≈643.7m
[DCF] Fair Price = 24.82 (EV 20.51b - Net Debt 12.51b = Equity 8.00b / Shares 322.2m; r=5.90% [WACC]; 5y FCF grow -40.0% → 2.90% )
EPS Correlation: -83.03 | EPS CAGR: -58.05% | SUE: -3.95 | # QB: 0
Revenue Correlation: -92.94 | Revenue CAGR: -15.20% | SUE: 0.26 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.80 | Chg7d=+0.000 | Chg30d=-0.163 | Revisions Net=-6 | Analysts=15
EPS current Year (2026-12-31): EPS=2.62 | Chg7d=+0.062 | Chg30d=-0.708 | Revisions Net=-6 | Growth EPS=+54.4% | Growth Revenue=-2.6%
EPS next Year (2027-12-31): EPS=3.77 | Chg7d=-0.052 | Chg30d=-0.810 | Revisions Net=-8 | Growth EPS=+43.6% | Growth Revenue=+0.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Next Quarter)